Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Dyne Therapeutics Presents New Preclinical Data for its globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,184,840 shares of the company’s stock, valued at approximately $15,758,000. Frazier Life Sciences Management L.P. owned 1.93% of Dyne Therapeutics at […]
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have received a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price […]
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Jefferies Financial Group from $36.00 to $42.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock. DYN has been the topic of several other research reports. Morgan Stanley assumed coverage on Dyne […]
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) had its price objective increased by research analysts at Chardan Capital from $31.00 to $42.00 in a note issued to investors on Tuesday, Briefing.com reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 18.71% from the […]
WALTHAM, Mass., March 27, 2024 -- Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically...
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target hoisted by Chardan Capital from $20.00 to $31.00 in a research note issued to investors on Friday, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock. Several other research firms have also weighed in on DYN. StockNews.com upgraded shares of […]